Judge dismisses Lilly's tirzepatide false-advertising suit against Willow Health

A federal judge in the Central District of California threw out Eli Lilly's lawsuit against Willow Health Services with prejudice on Feb. 3, 2026, ending the case at the pleading stage. The order granted Willow's motion to dismiss Lilly's false-advertising claims under the Lanham Act and refused Lilly permission to file an amended complaint ^[1].

Lilly's complaint centered on how Willow marketed compounded tirzepatide. Lilly said the products were not FDA-approved but were described as clinically tested, scientifically validated or superior. Lilly also said Willow suggested its products were equivalent to Mounjaro and Zepbound, the company's FDA-approved tirzepatide medicines, and promoted an oral tirzepatide product even though no FDA-approved oral version exists. Lilly told the court the marketing misled consumers, pulled sales away from its drugs and damaged its reputation. The suit was a private false-advertising case; Lilly did not bring FDA enforcement claims ^[1].

The judge's reasoning rested on standing and causation rather than on whether Willow's advertising was truthful or its products safe. Lilly cleared part of the test: the court accepted that the two companies compete directly and that Lilly had plausibly described a commercial injury at a general level, something earlier drafts of the complaint had not managed. But the Lanham Act asks for more than an injury. It also requires a close causal link between the advertising and the harm ^[1].

That link is where the case collapsed. Prescription drugs are not bought straight from the seller by consumers, the court noted, because a physician has to write the prescription first. Advertising on its own therefore cannot be the proximate cause of a manufacturer's lost sales; the prescribing decision stands in between. Lilly did not point to specific sales it lost, did not tie patients' exposure to Willow's ads to prescribing decisions, and did not show the near one-to-one relationship the court said was needed. Since Lilly had already amended the complaint once, the judge concluded another attempt would be futile and dismissed with prejudice ^[1].

The order does not decide whether Willow's marketing was accurate, whether compounded tirzepatide is safe or effective, whether an oral tirzepatide product works, or whether telehealth compounding complies with FDA rules. The court never reached those questions because the case failed earlier. The dismissal is procedural, not a verdict on the products ^[1].

Why it matters for patients

Anyone weighing compounded GLP-1 medicines gets no answers from this ruling about safety, effectiveness or legality. The court left those questions untouched ^[1]. What the decision narrows is one avenue of attack: Lanham Act false-advertising claims brought by brand manufacturers against compounding telehealth businesses.

Other kinds of legal pressure are unaffected. The ruling does not speak to FDA enforcement, state pharmacy board actions, consumer protection lawsuits, false claims or insurance litigation, or cases built on manufacturing, safety or misbranding instead of advertising causation. Those categories continue, and many GLP-1 compounding cases are moving forward under FDA regulatory theories, state unfair-competition laws, consumer deception statutes, and product liability or adverse-event claims ^[1].

The decision is expected to surface again as other GLP-1 cases are litigated, especially in motions to dismiss and defense filings arguing that the prescribing step breaks the chain between advertising and lost sales. The same logic could be raised in Lilly's other suits against telehealth companies, in actions by Novo Nordisk or other manufacturers, and in any Lanham Act dispute involving prescription-only drugs ^[1]. How other judges will respond has not been reported. No further dates in this case have been disclosed, and the source describes the matter as closed in this court ^[1].